Chiba-based Biomatrix Research Develops Diagnostic Antibody Chip
This article was originally published in PharmAsia News
Executive Summary
Chiba-based Biomatrix Research has developed an antibody chip that can diagnose simple diseases. The company coats glass plates with antibodies that respond to certain proteins, and when sample fluids are applied to the antibodies, certain diseases can be detected by the kinds of antibodies that responded. Biomatrix confirmed the results by testing human blood samples. The product's commercialization is planned in 2009. The company plans to sell it to domestic and overseas research facilities after 2009. (Click here for more - Japanese language
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.